2025-01-22 - Analysis Report
## Intuitive Surgical Inc. (ISRG) Stock Analysis Report

**1. Performance Summary & Comparison to S&P 500 (VOO):**

Intuitive Surgical Inc. (ISRG) is a company that manufactures and sells da Vinci surgical systems and related instruments.

The cumulative return of ISRG is significantly higher than that of the S&P 500 (VOO) over the analyzed period.  The difference in cumulative returns is 220.2%, representing a substantially outsized performance compared to the benchmark index. The relative divergence, while high at 100%, indicates that the current difference is at the historical maximum observed in the provided dataset.  This does not necessarily imply future outperformance.

| Year Range | ISRG CAGR | VOO CAGR (Implied) | ISRG Alpha | ISRG Beta |
|---|---|---|---|---|
| 2015-2017  | 73.0% | N/A | 46.0% | 0.0 |
| 2016-2018  | 88.0% | N/A | 73.0% | 0.0 |
| 2017-2019  | 102.0% | N/A | 71.0% | 0.0 |
| 2018-2020  | 97.0% | N/A | 63.0% | 0.0 |
| 2019-2021  | 137.0% | N/A | 57.0% | 0.0 |
| 2020-2022  | 7.0% | N/A | 0.0% | 0.0 |
| 2021-2023  | 2.0% | N/A | -22.0% | 0.0 |
| 2022-2024  | 60.0% | N/A | 38.0% | 0.0 |
| 2023-2025  | 218.0% | N/A | 147.0% | 0.0 |

**Note:** The VOO CAGR is not directly provided and therefore can't be accurately calculated for comparison. The Alpha values shown seem unusually high and possibly represent something other than the traditional alpha calculation.  Further investigation is needed to understand the precise meaning of these alpha figures. Beta values of 0.0 are unrealistic and suggest a problem with the data provided.


**2. Recent Price Movement:**

* **Closing Price:** $604.12
* **5-Day Moving Average:** $579.97
* **20-Day Moving Average:** $544.99
* **60-Day Moving Average:** $536.35

The price is currently trading above all three moving averages, suggesting a bullish trend.  The recent price increase of $1.937 indicates a positive momentum in the short term.

**3. Technical Indicators and Expected Return:**

* **RSI:** 75.98 (High, approaching overbought territory)
* **PPO:** 1.32 (Positive, indicating bullish momentum)
* **Relative Strength (20-day change):** +3.7% (Short-term upward trend)
* **Expected Return (2+ years):** 16.6% (Above S&P 500)

The high RSI suggests the stock might be overbought, raising the possibility of a short-term correction.  However, the positive PPO and recent price action suggest continued bullish momentum. The high expected return is notable, but it's crucial to consider the associated risk.


**4. Recent Earnings Analysis:**

| Date       | EPS   | Revenue      |
|------------|-------|--------------|
| 2024-10-18 | $1.59 | $2.04 Billion |
| 2024-07-19 | $1.48 | $2.01 Billion |
| 2024-04-19 | $1.54 | $1.89 Billion |
| 2023-10-20 | $1.18 | $1.74 Billion |
| 2024-10-18 | $1.18 | $1.74 Billion | *(Duplicate Entry - needs clarification)*

Revenue shows a generally upward trend, while EPS fluctuates. The duplicate entry for October 18th, 2024 needs clarification to ensure data accuracy.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter     | Revenue    | Profit Margin |
|-------------|------------|---------------|
| 2024-09-30  | $2.04B     | 67.41%        |
| 2024-06-30  | $2.01B     | 68.30%        |
| 2024-03-31  | $1.89B     | 65.87%        |
| 2023-12-31  | $1.93B     | 66.24%        |
| 2023-09-30  | $1.74B     | 66.94%        |

Revenue shows growth, and profit margins remain consistently high, indicating strong financial health.

**Capital and Profitability:**

| Quarter     | Equity     | ROE          |
|-------------|------------|--------------|
| 2024-09-30  | $15.58B    | 3.63%        |
| 2024-06-30  | $14.71B    | 3.58%        |
| 2024-03-31  | $13.96B    | 3.90%        |
| 2023-12-31  | $13.31B    | 4.56%        |
| 2023-09-30  | $12.54B    | 3.32%        |

Equity is steadily increasing, although ROE shows some fluctuation.


**7. Overall Analysis:**

ISRG demonstrates strong historical performance significantly exceeding the S&P 500.  Recent financial results show robust revenue growth and high profit margins. However, the high RSI suggests potential short-term overvaluation.  The provided Alpha and Beta figures require further investigation due to inconsistencies. The high expected return is attractive for long-term investors, but this should be balanced against the inherent risk in any individual stock.  A thorough review of the duplicated earnings data point and the meaning of the alpha and beta values is crucial before making any investment decisions.


**8. Disclaimer:** This analysis is based solely on the provided data and should not be considered financial advice.  Independent research and consultation with a financial advisor are strongly recommended before making any investment decisions.  The inaccuracies in the provided data (duplicated earnings, unrealistic beta) significantly impact the reliability of this analysis.
